Eidos Therapeutics, Inc

Home » Eidos Therapeutics, Inc

IPO

Eidos Therapeutics, Inc

We are a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR.

Symbol

EIDX

Price Range
$15.00 - $17.00

Final Shares
6,250,000

Anticipated Date
TBD

Underwriters
J.P. Morgan, BofA Merrill Lynch, Barclays

To view the prospectus for Eidos Therapeutics, Inc IPO, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253